Review article on COVID-19 and Guillain-Barré syndrome

The tale COVID infection pandemic or as far as we might be concerned better, COVID-19, has assaulted society on a worldwide scale. For the unenlightened, the sickness is brought about by the specific infection Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is only from time to time that we have a pandemic seething on that has carried with itself a particularly humongous size of harm and on each and every front of the human culture, be it clinical, practical, social or pretty much anything. Theemerging coronavirus disease 2019 (COVID-19) has neurological symptoms comparable to that of the Extreme Acute Respiratory Syndrome Coronavirus (SARS-CoV) and MERS-CoV. Medical symptoms such as pain in head, vomiting, nausea, dizziness, muscle pain, anosmia, ageusia, and disorder of consciousness are present in COVID-19 affected people. These signs confirm that the COVID-19 infection affects the nervous system. But nerve affecting manifestations of COVID-19 infection are underreported. Guillain-Barré Syndrome (GBS) is a condition that often arises in various forms. According to the evaluation case reports so far from the start of COVID-19 infection, GBS could be associated with COVID-19 infection. There was a systematic review and published cases that suggested that a broad age range with male predominance was affected. There were respiratory and/or systemic symptoms in most patients and they developed GBS manifestations after COVID-19. However, asymptomatic cases of COVID-19 have also been identified. The distribution of clinical variants and electrophysiological subtypes is close to that of classical GBS, with a higher prevalence of classical sensorimotor form and acute inflammatory demyelinating polyneuropathy. It seems like it is important to pay attention to the neurological effects of COVID-19.